Results 171 to 179 of about 6,241 (179)

Conventional type 1 dendritic cells (cDC1) as cancer therapeutics: challenges and opportunities

Expert Opinion on Biological Therapy, 2021
The use of dendritic cell (DC)-based cancer vaccines over three decades has shown them to be a safe therapeutic approach against a range of hematological and solid malignancies. However, underwhelming and inconsistent results from clinical trials have seen them move in and out of favor. The limitations of ex vivo generated monocyte-derived DC (MoDC) in
Phillip Johnson, Nikita Rosendahl, Kristen J Radford   +2 more
openaire   +2 more sources

Adipose cDC1s contribute to obesity-associated inflammation through STING-dependent IL-12 production

Nature Metabolism, 2023
Obesity is associated with chronic low-grade white adipose tissue (WAT) inflammation that can contribute to the development of insulin resistance in mammals. Previous studies have identified interleukin (IL)-12 as a critical upstream regulator of WAT inflammation and metabolic dysfunction during obesity.
Andrew D. Hildreth, Eddie T. Padilla, Meha Gupta, Yung Yu Wong, Ryan Sun, Akshara R. Legala, Timothy E. O’Sullivan   +6 more
openaire   +2 more sources

Wnt4 controls early cDC1 commitment to suppress Type 2 immunity

The Journal of Immunology, 2019
Abstract Whether conventional dendritic cells (cDC) acquire subset identity under direction of regenerative glycoproteins is unknown. We demonstrate that Wnt4, a beta-catenin independent Wnt ligand, is necessary and sufficient for pre-cDC1 BM specification. CD11c-restricted Wnt4 deficiency reduced mature cDC1 numbers in BM, spleen, lung,
Li-Yin Hung, John L Johnson, Yingbiao Ji, David A Christian, Karl R Herbine, Christopher F Pastore, De’Broski R Herbert   +6 more
openaire   +1 more source

cDC1 craves glutamine for its glory

Nature Immunology, 2023
Stefania Vilbois, Jaeoh Park, Ping-Chih Ho   +2 more
openaire   +2 more sources

Ms4a7 expression in cDC1s determines cross-presentation and antitumor immunity

Science
Conventional type 1 dendritic cells (cDC1s) capture antigens in peripheral tissues and migrate to draining lymph nodes (dLNs) to prime antigen-specific CD8 + T cells. How tumor antigens are processed to activate CD8 + T cell immunity is not well ...
Bowen Xie, Bowen Yuan, Xiaohong Zhao, Tian Xie, Ruifeng Li, Peng Wei, Qinli Sun, Wenbo Hu, Birui Pan, Yongzhen Chen, Kun Wei, Zixuan Zhao, Lei Yuan, Xuan Zhong, Xue Bai, Qiuyan Lan, Lei Qin, Ling Ni, Chen Dong   +18 more
openaire   +1 more source

Faculty Opinions recommendation of cDC1 Vaccines Drive Tumor Rejection by Direct Presentation Independently of Host cDC1.

Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature, 2022
openaire   +1 more source

Mechanisms of Cross-Presentation by cDC1s

2020
openaire   +1 more source

CDC1

2008
openaire   +1 more source

Violence against women as a public health issueComments from the CDC1

American Journal of Preventive Medicine, 2000
Linda E Saltzman, Yvonne T Green, James S Marks, Stephen B Thacker   +3 more
openaire   +1 more source